Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell Lymphoma

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Murata, Takayuki ^a   Iwata, Seiko ^b   Siddiquey, Mohammed Nure Alam ^b   Kanazawa, Tetsuhiro ^b   Goshima, Fumi ^b   Kawashima, Daisuke ^a   Kimura, Hiroshi ^b   Tsurumi, Tatsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN KINASE B; RADICICOL; STAT PROTEIN; TANESPIMYCIN; TUMOR NECROSIS FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; MACROLIDE; MATRIX PROTEIN; MOLECULAR LIBRARY;

ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; EPSTEIN BARR VIRUS; IMMUNE DEFICIENCY; INFECTION; INTRACELLULAR SIGNALING; NK T CELL LYMPHOMA; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; EPSTEIN-BARR VIRUS INFECTIONS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOMA; MOLECULAR LIBRARY; MOUSE; NATURAL KILLER CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME;

HUMAN HERPESVIRUS 4; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BENZOQUINONES; CELL PROLIFERATION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOCOMPROMISED HOST; KILLER CELLS, NATURAL; LACTAMS, MACROCYCLIC; LYMPHOMA; MACROLIDES; MICE; MICE, INBRED NOD; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; TUMOR BURDEN; VIRAL MATRIX PROTEINS;

EID: 84877022289     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063566     Document Type: Article

References (48)

1. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, et al. (2001) Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98: 280-286.
2. Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, et al. (2001) Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood 98: 3173-3174.
3. Kimura H, (2006) Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16: 251-261.
4. Fox CP, Shannon-Lowe C, Rowe M, (2011) Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2: 8.
5. Kwong YL, (2005) Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19: 2186-2194.
6. Soni V, Cahir-McFarland E, Kieff E, (2007) LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol 597: 173-187.
7. Lam N, Sugden B, (2003) CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 15: 9-16.
8. Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, et al. (2007) EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog 3: e166.
9. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, et al. (1998) Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 95: 11963-11968.
10. Lam N, Sugden B, (2003) LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments. EMBO J 22: 3027-3038.
11. Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseno C, et al. (2005) Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 24: 1711-1717.
12. Kilger E, Kieser A, Baumann M, Hammerschmidt W, (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17: 1700-1709.
13. Kieser A, Kaiser C, Hammerschmidt W, (1999) LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 18: 2511-2521.
14. Paine E, Scheinman RI, Baldwin AS Jr, Raab-Traub N, (1995) Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol 69: 4572-4576.
15. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, et al. (1999) Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286: 300-303.
16. Workman P, Burrows F, Neckers L, Rosen N, (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
17. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
18. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
19. Jhaveri K, Taldone T, Modi S, Chiosis G, (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823: 742-755.
20. Usmani SZ, Chiosis G, (2011) HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 11Suppl 1: S77-81.
21. Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, et al. (2001) Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 97: 708-713.
22. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, et al. (2003) Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 121: 805-814.
23. Miller G, Lipman M, (1973) Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70: 190-194.
24. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, et al. (2012) Epigenetic Histone Modification of Epstein-Barr Virus BZLF1 Promoter during Latency and Reactivation in Raji Cells. J Virol 86: 4752-4761.
25. Noda C, Murata T, Kanda T, Yoshiyama H, Sugimoto A, et al. (2011) Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1. J Biol Chem 286: 42524-42533.
26. Kimura M, (2008) IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription. FEBS Lett 582: 2833-2837.
27. Jeon YK, Park CH, Kim KY, Li YC, Kim J, et al. (2007) The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol 213: 170-179.
28. Sun X, Barlow EA, Ma S, Hagemeier SR, Duellman SJ, et al. (2010) Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci U S A 107: 3146-3151.
29. Imadome K, Yajima M, Arai A, Nakazawa A, Kawano F, et al. (2011) Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 7: e1002326.
30. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, et al. (1995) Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 69: 253-262.
31. Laux G, Adam B, Strobl LJ, Moreau-Gachelin F, (1994) The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J 13: 5624-5632.
32. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E, (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91: 7568-7572.
33. Kis LL, Gerasimcik N, Salamon D, Persson EK, Nagy N, et al. (2011) STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 117: 165-174.
34. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, et al. (2010) IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci U S A 107: 872-877.
35. Kis LL, Takahara M, Nagy N, Klein G, Klein E, (2006) IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107: 2928-2935.
36. Konforte D, Simard N, Paige CJ, (2008) Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology 374: 100-113.
37. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, et al. (2001) Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75: 2929-2937.
38. Chen H, Hutt-Fletcher L, Cao L, Hayward SD, (2003) A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol 77: 4139-4148.
39. Schoof N, von Bonin F, Trumper L, Kube D, (2009) HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells. Cell Commun Signal 7: 17.
40. Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, et al. (2006) Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119: 2775-2783.
41. Zhou J, Zhang J, Lichtenheld MG, Meadows GG, (2002) A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling. J Immunol 169: 1319-1325.
42. Rakitina TV, Vasilevskaya IA, O'Dwyer PJ, (2003) Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res 63: 8600-8605.
43. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, et al. (2006) 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 66: 1089-1095.
44. Waltzer L, Logeat F, Brou C, Israel A, Sergeant A, et al. (1994) The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J 13: 5633-5638.
45. Sjoblom A, Jansson A, Yang W, Lain S, Nilsson T, et al. (1995) PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J Gen Virol 76 (Pt 11): 2679-2692.
46. Sjoblom A, Nerstedt A, Jansson A, Rymo L, (1995) Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. J Gen Virol 76 (Pt 11): 2669-2678.
47. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, et al. (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855.
48. Morceau F, Buck I, Dicato M, Diederich M, (2008) Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation. Biofactors 34: 313-329.